Organogenesis ORGO
1.41
(0.01)
(0.70%)
as of 25 Sep
- Market cap
- $207.1M
- P/E
- 0.0×
Follow ORGO
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(5.02%) | 7.11% | (5.97%) | (53.31%) | |
| (2.80%) | 3.65% | (2.95%) | (23.44%) | ||
ROIC |
(2.71%) | 12.78% | 0.97% | (19.97%) | |
Return on Tangible Assets |
(4.66%) | 5.47% | (4.90%) | (41.53%) | |
Average Days of Receivables |
132.42 | 140.68 | 82.90 | 80.54 | |
Free Cash Flow per Share |
(0.41) | (0.19) | 0.13 | 0.16 | |
Free Cash Flow |
(51.65) | (24.46) | 17.08 | 20.84 | |
Capital Expenditures |
(12.86) | (14.15) | (13.67) | (11.13) | |
Piotroski F-Score |
2.00 | 3.00 | 4.00 | 3.00 | |
| Other line items | |||||
Cash ROIC |
(12.06%) | (2.53%) | 8.81% | 15.53% | |
Accounts Receivable Turnover |
3.45 | 3.45 | 4.67 | 4.13 | |
Accounts Payable Turnover |
3.70 | 4.52 | 5.24 | 4.60 | |
Inventory Turnover |
3.56 | 4.93 | 4.83 | 4.35 | |
Average Days of Payables |
123.72 | 84.80 | 74.83 | 78.84 | |
Days of Inventory on Hand |
121.76 | 78.63 | 74.34 | 78.81 | |
Tax Rate |
(1.16) | (0.21) | (0.36) | 1.42 | |
Research and Development Expense of Revenue |
9.84% | 7.90% | 9.53% | 12.45% | |
Selling, General and Administrative Expense of Revenue |
64.47% | 57.83% | 61.96% | 65.38% | |
Share Based Compensation of Revenue |
2.55% | 2.36% | 2.64% | 3.08% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
2.90 | (0.51) | (2.11) | (0.31) | |
Depreciation/Fixed assets |
0.34 | 0.26 | 0.32 | 0.32 | |
Capex/Depreciation |
(0.49) | (0.53) | (0.41) | (0.34) | |
Revenue per Share |
3.67 | 4.45 | 4.03 | 3.56 | |
Operating CF per Share |
(0.31) | (0.08) | 0.24 | 0.25 | |
Capex per Share |
(0.10) | (0.11) | (0.11) | (0.09) | |
Capex to Sales |
0.03 | 0.03 | 0.03 | 0.02 | |
Net Profit Margin |
(2.88%) | 3.55% | (2.83%) | (22.23%) |
Columns are period end dates